Abstract | OBJECTIVE: DATA SOURCES: Databases searched included Medline, PsychInfo, the International Pharmaceutical Abstracts, and Google Scholar. Search terms included drug-induced akathisia, psychomotor agitation, drug-induced side effect, movement disorders, and extrapyramidal symptoms. These search terms were cross-referenced with selective serotonin reuptake inhibitors and each of the currently marketed SSRIs: fluoxetine, fluvoxamine, sertraline, paroxetine, citalopram, and escitalopram. STUDY SELECTION: Relevant articles were chosen if they specifically mentioned the word akathisia. Case reports were chosen based on a clear view that an SSRI was a contributing or causative agent of akathisia. DATA SYNTHESIS: CONCLUSION: Pharmacists can play an active role in recognizing akathisia by being aware of its characteristics, conducting a thorough medication history to identify causative agents, and using BARS to evaluate patients. These efforts may preclude unnecessary discomfort for the patient and reduce the potential for nonadherence induced by akathisia.
|
Authors | Lindsey P Koliscak, Eugene H Makela |
Journal | Journal of the American Pharmacists Association : JAPhA
(J Am Pharm Assoc (2003))
2009 Mar-Apr
Vol. 49
Issue 2
Pg. e28-36; quiz e37-8
ISSN: 1544-3450 [Electronic] United States |
PMID | 19289334
(Publication Type: Journal Article, Review)
|
Chemical References |
- Serotonin Uptake Inhibitors
|
Topics |
- Akathisia, Drug-Induced
(diagnosis, etiology, therapy)
- Animals
- Humans
- Risk Factors
- Selective Serotonin Reuptake Inhibitors
(adverse effects, therapeutic use)
|